RASGenix Srl

Founded as a spin-off from the University of Turin, RASGenix is driving the development of groundbreaking pharmaceutical technologies for drug discovery in oncology. With a focus on RAS-dependent diseases, our company offers a comprehensive range of customisable preclinical services backed by decades of academic and translational research. Our global team of experts delivers precision-driven solutions tailored to pharmaceutical and biotechnology companies worldwide, shaping the future of oncological targeted therapies.